[A15-21] Dasabuvir / ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)
Last updated 16.07.2015
Project no.:
A15-21
Commission:
Commission awarded on 10.06.2015 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment. G-BA decisions on dasabuvir and ombitasvir/paritaprevir/ritonavir.
| Project no. | Title | Status |
|---|---|---|
| A15-04 | Ombitasvir/paritaprevir/ritonavir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A15-03 | Dasabuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2015-07-16 A G-BA decision was published.
G-BA documents on this decision (dasabuvir)
G-BA documents on this decision (ombitasvir/paritaprevir/ritonavir )